StemCyte Overview

  • Founded
  • 1997

Founded
  • Status
  • Private

  • Employees
  • 109

Employees
  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 8

StemCyte General Information

Description

Operator of a regenerative cell therapy company intended to focus on stem cell therapy and regenerative medicine. The company has established an inventory of genetically diverse cord blood banks as the feedstuff, it has utilized the same cord tissue products to develop a proprietary regenerative therapy platform technology, enabling physicians to cure life-threatening diseases such as spinal cord injury, chronic/acute stroke, cartilage repair, and other neurological disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Primary Office
  • 13800 Live Oak Avenue
  • Baldwin Park, CA 91706
  • United States
+1 (866) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

StemCyte Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private 08-Mar-2022 000.00 Completed Clinical Trials - Phase 2
10. Later Stage VC 000.00 Completed Clinical Trials - Phase 2
9. Secondary Transaction - Private 000.00 Completed Generating Revenue
8. Debt - General 23-Nov-2010 000.00 Completed Generating Revenue
7. Debt - General 01-Jun-2009 000 000.00 Completed Generating Revenue
6. Later Stage VC 02-Oct-2007 00.000 000.00 Completed Generating Revenue
5. Later Stage VC (Series 3) 14-Jul-2006 00.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series D) 20-May-2002 00.000 000.00 0000 Completed Startup
3. Later Stage VC (Series C) 14-Feb-2002 $7.4M $12.9M 00000 Completed Startup
2. Early Stage VC (Series B) 02-Oct-2000 $5.46M $5.46M 000.00 Completed Startup
To view StemCyte’s complete valuation and funding history, request access »

StemCyte Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 0,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series C 000,000 00.000000 00 000 000 00 00.00 0.000
Series B 1,821,000 $0.001000 7% $3 $3 1x $2.5 11.51%
Series A 1,850,000 $0.001000 7% $2.5 $2.5 1x $1 24.36%
To view StemCyte’s complete cap table history, request access »

StemCyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a regenerative cell therapy company intended to focus on stem cell therapy and regenerative medicine. The co
Biotechnology
Baldwin Park, CA
109 As of 2022
000.00
00000000000 000.00

000000

t esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
00000 0000000000 00000000
Waltham, MA
000000&0

000000

lor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
00000 0000000000 00000000
Chennai, India
0000 As of 0000
00.000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

StemCyte Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Viacord Corporate Backed or Acquired Waltham, MA 000000&0
00000000 000000000 Venture Capital-Backed Chennai, India 0000 00.000 0000000000 0 00.000
0000 00000 0000000 Formerly PE-Backed Los Angeles, CA 000 00000 000000000000
00000000 00000 Formerly PE-Backed Singapore, Singapore 000 000.00 000000000 000.00
0000-0000 00000000 Corporation Oldsmar, FL 00 00000 000000&0
You’re viewing 5 of 5 competitors. Get the full list »

StemCyte Patents

StemCyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3137570-A1 High concentration cell packaging and shipping Pending 15-May-2019 0000000000
US-20120034197-A1 Hiv-resistant stem cells and uses thereof Abandoned 09-Apr-2009 000000000 00
US-20140227236-A1 Hiv-resistant stem cells and uses thereof Abandoned 09-Apr-2009 000000000 0
US-20080008693-A1 Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use Granted 02-Jun-2005 0000000000 0
US-8048619-B2 Method of treating a hematopoietic associated disease or disorder with plasma-depleted, but not erythrocyte-depleted cord blood compositions Active 02-Jun-2005 C12N5/0647 00
To view StemCyte’s complete patent history, request access »

StemCyte Executive Team (10)

Name Title Board Seat Contact Info
Jonas Wang Ph.D Chief Executive Officer, President & Chairman
Satish TN Chief Operating Officer
Wise Young Ph.D Chief Science and Medical Advisor
Shinn-Zong Lin Chief Medical Officer
Kenneth Giacin Chief Business Advisor & Vice Chairman
You’re viewing 5 of 10 executive team members. Get the full list »

StemCyte Board Members (8)

Name Representing Role Since
Chris Tsai Self Board Member 000 0000
Eli Wang Self Board Member 000 0000
George Lee Ph.D Amkey Ventures Board Member 000 0000
Jonas Wang Ph.D StemCyte Chief Executive Officer, President & Chairman 000 0000
Kenneth Giacin Self Chief Business Advisor & Vice Chairman 000 0000
You’re viewing 5 of 8 board members. Get the full list »

StemCyte Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

StemCyte Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Amkey Ventures Venture Capital Minority 000 0000 000000 0
Fairbridge Venture Partners Venture Capital Minority 000 0000 000000 0
Kenson Ventures Venture Capital Minority 000 0000 000000 0
Kuwait Life Sciences Company Venture Capital Minority 000 0000 000000 0
Montage Capital Mezzanine Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »